Refine Search

New Search

Advanced search

Results: 112

(searched for: Recurrent-pregnancy-loss-causes-and-management)
Page of 12
Articles per Page
by
Show export options
  Select all
Binit Vaidya, Shweta Nakarmi, Rakshya Joshi, Rikesh Baral
Journal of Nepal Medical Association, Volume 57, pp 133-145; doi:10.31729/jnma.4226

Abstract: Anti-phospholipid Antibody Syndrome or Hugh's syndrome is a heterogeneous disorder, first fully described in 1980s. The syndrome is
caused
by the presence of specific antibodies against phospholipid binding plasma proteins in the serum of the patient, with or without underlying autoimmune diseases, that
causes
prolongation of tests of coagulation. High index of clinical suspicion is required for diagnosis of Anti-phospholipid Antibody Syndrome. Stroke or myocardial infarction in young, unprovoked
recurrent
deep vein thrombosis
and
recurrent
pregnancy
loss
are typical scenarios where Anti-Phospholipid Antibody Syndrome should be suspected. Presence of non-criteria manifestations like livedo reticularis, skin ulcers, nephropathy, valvular heart disease
and
thrombocytopenia adds to diagnostic clue for presence of Anti-Phospholipid Antibody Syndrome. Treatment of Anti-Phospholipid Antibody Syndrome has preventive
and
therapeutic aspects that usually focus on thrombotic
and
obstetric manifestations of the disease. Therapeutic anti-coagulation with heparin followed by warfarin is required for patients presenting with acute thrombosis. Those with venous thrombosis are given moderate intensity warfarin International Normalized Ratio, 2-3), whereas those with arterial thrombosis or
recurrent
venous thrombosis even on warfarin are treated with high intensity warfarin (International Normalized Ratio, 3-4). Similarly, anticoagulation with heparin is advised in patients with obstetric Anti-Phospholipid Antibody Syndrome throughout
pregnancy
and
up to six weeks postpartum. Treatment recommendations are still not clear for asymptomatic Anti-Phospholipid Antibody Syndrome positive patients
and
in those with non-criteria manifestations of the disease. Steroids, intravenous immunoglobulin
and
immunosuppressant are reported to be effective in severe cases of catastrophic antiphospholid syndrome characterized by rapid small vessel thrombotic involvement of multiple organ systems. Studies are evaluating the efficacy of direct thrombin inhibitors in the
management
of refractory cases. Keywords: anticoagulants; anti-phospholipid syndrome; obstetric APS; thrombotic APS.
S Zeybek, E Tepeli, G O Cetin, V Caner, H Senol, B Yildirim, G Bagci
Balkan Journal of Medical Genetics, Volume 22, pp 21-28; doi:10.2478/bjmg-2019-0002

Abstract: Pentraxin 3 (PTX3), a prototypical member of the long pentraxin subfamily, is a evolutionarily conserved multimeric pattern recognition receptor involved in the humoral component of the innate immune system. Pentraxin 3 is released when tissue is stressed or damaged,
and
interacts with many different ligands. Pentraxin 3 exerts a pivotal role both as a regulator
and
as an indicator of inflammatory response in the pathogenesis of many diseases such as sepsis, vasculitis
and
preeclampsia. Uncontrolled inflammatory response is considered a major
cause
of unexplained
recurrent
pregnancy
loss
(URPL). We determined the PTX3 messenger ribonucleic acid (mRNA)
and
protein expression levels in placentai tissues from 50 women with URPL,
and
made comparison with those in 50 age-matched control subjects. In quantitative real-time polymerase chain reaction (qRT-PCR)
and
immunohistochemistry analyses, PTX3 mRNA
and
protein levels, respectively, were significantly increased in URPL patients compared with their respective controls (p = 0.0001). Although no significant correlations were identified between PTX3 expression levels
and
clinical parameters such as maternal age, numbers of previous
pregnancy
losses
,
and
gestational age at miscarriage, PTX3 mRNA expression was significantly higher in patients with no live births than in women with previous live births (p = 0.0001). Our study suggests that tissue-specific expression of PTX3 is associated with URPL. Further larger studies are required to determine whether PTX3 expression can be used as a biomarker to
manage
URPL in routine clinical practice.
Andreea Radu, Stefan Cristian Dudu, Anca Ciobanu, Gheorghe Peltecu, George Iancu, Radu Botezatu, Nicolae Gica, Sciprofile linkAnca Panaitescu
Published: 1 June 2019
Abstract: The antiphospholipid syndrome (APS or Hughes Syndrome) is a systemic autoimmune disease characterised by the presence of specific
and
persistent circulating antiphospholipid antibodies (APL)
and
the subsequent morbidities they
cause
, including
pregnancy
complications
and
thrombosis. The three main antiphospholipid antibodies are: lupus anticoagulant (LA); anticardiolipin antibodies (aCL) IgG
and
IgM;
and
anti-â2-glycoprotein 1 IgG
and
IgM antibodies. Antiphospholipid syndrome is associated with
pregnancy
complications such as
recurrent
early fetal
loss
, fetal death, preeclampsia (PE),
and
fetal growth restriction (FGR). Although autoimmune disorders may have serious implication during
pregnancy
important advancements in
pregnancy
outcome have been reported in women with APL. The challenge arises in case of women refractory to conventional treatment (heparine/aspirin combination), which occurs in about 20-30% of cases. The
management
of pregnant women with non-criteria APS manifestations
and
that of APL carriers during their first
pregnancy
is also discussed. This paper aims to discuss the risk stratification, clinical
and
pregnancy
implications
and
current treatment strategies for pregnant women.
Sciprofile linkKarolina M. Stepien, Tarekegn Geberhiwot, Christian J. Hendriksz, Eileen P. Treacy
Journal of Inherited Metabolic Disease, Volume 42, pp 1136-1146; doi:10.1002/jimd.12096

The publisher has not yet granted permission to display this abstract.
Journal of Obstetrics and Gynaecology, Volume 39, pp 816-821; doi:10.1080/01443615.2019.1576600

The publisher has not yet granted permission to display this abstract.
Sciprofile linkNathan Blue, Jessica M. Page, Robert M. Silver
Published: 1 March 2019
Seminars in Perinatology, Volume 43, pp 66-73; doi:10.1053/j.semperi.2018.12.002

The publisher has not yet granted permission to display this abstract.
Human Reproductive and Prenatal Genetics pp 463-494; doi:10.1016/b978-0-12-813570-9.00021-8

The publisher has not yet granted permission to display this abstract.
Arima Nigam, Aruna Nigam, Nidhi Gupta, Abhinav Jain
Published: 1 January 2019
Indian Journal of Medical Specialities, Volume 10; doi:10.4103/injms.injms_67_19

The publisher has not yet granted permission to display this abstract.
D. Keith Edmonds
Dewhurst's Textbook of Obstetrics & Gynaecology pp 568-574; doi:10.1002/9781119211457.ch41

The publisher has not yet granted permission to display this abstract.
Maya Chetty, W. Colin Duncan
Obstetrics, Gynaecology & Reproductive Medicine, Volume 28, pp 164-170; doi:10.1016/j.ogrm.2018.04.005

The publisher has not yet granted permission to display this abstract.
Page of 12
Articles per Page
by
Show export options
  Select all